Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

Medicine & Life Sciences

• Adipokines 12%
• Adiponectin 22%
• Adipose Tissue 17%
• Apolipoprotein C-II 34%
• Apolipoprotein C-III 31%
• Apolipoproteins 12%
• Apolipoproteins E 11%
• Blood Vessels 6%
• C-Reactive Protein 18%
• Cell Adhesion Molecules 11%
• Fasting 8%
• Fenofibrate 86%
• Glucose 40%
• Glucose Clamp Technique 12%
• Glucose Tolerance Test 10%
• HDL Cholesterol 19%
• Health Care Outcome Assessment 6%
• Indirect Calorimetry 13%
• Inflammation 37%
• Insulin 21%
• Insulin Resistance 43%
• Insulin Secretion 31%
• Interleukin-6 16%
• Leptin 10%
• Lipid Metabolism 61%
• Lipids 13%
• Lipoproteins 10%
• Liver 10%
• Metabolic Syndrome 58%
• Muscles 12%
• Nonesterified Fatty Acids 11%
• Palmitates 13%
• Peroxisome Proliferator-Activated Receptors 25%
• Placebos 22%
• Triglycerides 17%
• Vascular Cell Adhesion Molecule-1 12%

Chemical Compounds

• Anti Atherogenis 11%
• Apolipoprotein 34%
• Calorimetry 6%
• Fenofibrate 100%
• Glucose 47%
• High-Density Lipoprotein Cholesterol 22%
• Insulin Derivative 65%
• Leptin 12%
• Lipid 44%
• Lipoprotein 7%
• Marker 56%
• Metabolic 51%
• Peroxisome Proliferator Activated Receptor Agonist 12%
• Pharmacological Metabolism 49%
• Plasma 17%
• Protein 5%
• Resistance 8%
• Triglyceride 14%